Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: A possible mechanism for the antiarthritic activity of Au(I)

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 20, 2004, Pages 5113-5116

  Chircorian, Aida ^a   Barrios, Amy M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; CYSTEINE PROTEINASE; GOLD COMPLEX; LYSOSOME ENZYME; THIOMALIC ACID;

ARTICLE; CONCENTRATION RESPONSE; DRUG POTENCY; ENZYME INHIBITION; GOLD THERAPY; IC 50;

ANIMALS; ANTIRHEUMATIC AGENTS; AURANOFIN; CATHEPSIN B; CATHEPSINS; CHLORIDES; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; GOLD COMPOUNDS; GOLD SODIUM THIOMALATE; HUMANS; LIVER; LYSOSOMES; PARAMECIUM TETRAURELIA;

EID: 4544310043     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.07.073     Document Type: Article

References (32)

1. S.P. Fricker Gold Bull. 29 1996 53 60
2. D.H. Brown, and W.E. Smith Chem. Soc. Rev. 9 1980 217 240
3. J. Forestier J. Lab. Clin. Med. 20 1935 827 840
4. B.M. Sutton, E. McGusty, D.T. Walz, and M.J. DiMartino J. Med. Chem. 15 1972 1095 1098
5. M.C. Pugh, and C.B. Pugh Clin. Pharm. 6 1987 475 491
6. D.S. Pisetsky, and E.W. St. Clair JAMA 286 2001 2787 2790
7. D.G. Baker, and J.L. Rabinowitz J. Clin. Pharmacol. 26 1986 2 21
8. C.F. Shaw III Chem. Rev. 99 1999 2589 2600
9. M. Chaffman, R.N. Brogden, R.C. Heel, T.M. Speight, and G.S. Avery Drugs 27 1984 378 424
10. A.A. Isab, and P.J. Sadler J. Chem. Soc., Dalton. Trans. 1982 135 141
11. H. Menninger, and H. Burkhardt Rheumatology 8 1983 84 98
12. K. Hashimoto, C.E. Whitehurst, T. Matsubara, K. Hirohata, and P.E. Lipsky J. Clin. Invest. 89 1992 1839 1848
13. M.P. Rigobello, G. Scutari, R. Boscolo, and A. Bindoli Br. J. Pharmacol. 136 2002 1162 1168
14. T.J. Hall, H. Jeker, H. Nyugen, and M. Schaeublin Inflamm. Res. 45 1996 230 233
15. K.-I. Jeon, J.-Y. Jeong, and D.-M. Jue J. Immunol. 2000 5981 5989
16. K.-I. Jeon, M.-S. Byun, and D.-M. Jue Exp. Mol. Med. 35 2003 61 66
17. J.V. Stoyanov, and N.L. Brown J. Biol. Chem. 278 2003 1407 1410
18. R.M. Snyder, C.K. Mirabelli, and S.T. Crooke Sem. Arthritis Rheum. 17 1987 71 80
19. S.K. Mallya, and H.E. Van Wart J. Biol. Chem. 264 1989 1594 1601
20. A. Baici, A. Camus, and N. Marsich Biochem. Pharmacol. 33 1984 1859 1865
21. R.S. Ennis, J.L. Granda, and A.S. Posner Arthritis Rheum. 11 1968 756 764
22. S. Paltemaa Acta Rheum. Scand. 14 1968 161 168
23. A.J. Lewis, J. Cottney, D.D. White, P.K. Fox, A. McNeillie, J. Dunlop, W.E. Smith, and D.H. Brown Agents Actions 10 1980 63 77
24. D. Rohozková, and F.S. Steven Br. J. Pharmacol. 79 1983 181 189
25. D. Kruze, K. Fehr, and A. Böni Z. Rheumatol. 35 1976 95 102
26. Enzyme activity assays: Standard conditions used to determine the activity of the purified enzymes against Z-Phe-Arg-MCA are described below. Substrate stocks were dissolved in DMSO and aliquots taken such that each reaction had the same amount of DMSO, which never exceeded 5% of the total reaction volume. The buffer used for all studies contained 20 mM sodium acetate, pH 5.5, 50 mM sodium chloride, 1.0 mM EDTA, and 0.01% Brij 35, with 400 μM DTT added to the buffer just prior to each reaction. In each reaction, the concentration of enzyme was fixed between 1 and 10 nM and the substrate concentration varied from 5 nM to 100 μM. The increase in fluorescence as the substrate was hydrolyzed was measured every 60 s for 30 min. Fluorescence was converted into concentration of 7-amino-4-methylcoumarin (MCA) produced using a standard curve of MCA fluorescence, and the data was fit to the Michaelis-Menten equation, providing kinetic parameters for each enzyme
27. 2Cl, which was insoluble at concentrations above 1 μM
28. S.J. Berners-Price, and P.J. Sadler Inorg. Chem. 25 1986 3822 3827
29. S.M. Cottrill, H.L. Sharma, D.B. Dyson, R.V. Parish, and C.A. McAuliffe J. Chem. Soc., Perkin Trans. 2 1989 53 58
30. The possibility of reversing the Au(I) inhibition of Paramecium tetraurelia cathepsin L was investigated by first preincubating the enzyme with 50 μM myochrysin for 1 h, then adding between 20 nM and 200 μM of thiomalic acid or reduced glutathione and incubating another 1 h. Finally, substrate was added to each mixture and the rate of reaction was determined
31. To determine the mode of inhibition, four different reactions were run where the substrate concentration was varied from 20 to 90 μM at inhibitor concentrations of 300 nM, 3, 30, and 300 μM
32. P.C. Engel Enzymology LABFAX 1996 Academic San Diego, CA